Organization: Wolfe Laboratories, Inc.
Location: Wolfe Laboratories' facility
134 Coolidge Avenue
Watertown, MA 02472
Date: November 8, 2012; 8:00am - 6:00pm
Program: This course is the latest in a series we started a few years ago, and it is intended to provide a foundation for people who are involved in early drug development.
Nanotechnology presents attractive solutions for the development of stable, commercially viable pharmaceutical products. Every nanoscale therapeutic presents a number of unique challenges that must be appropriately understood and addressed during the formulation development process. Fundamentals of Nanomedicine is designed to impart to scientists the tools and knowledge necessary to systematically approach the development of nanomedicines.
The course will provide an overview of the nanomedicine industry and detail the development of nanoscale therapeutics including small-molecule nanocrystals, polymer-based drugs, siRNA nanoparticles, and nanoparticles for targeted drug delivery. These case studies will be used to illustrate important aspects of product development to allow scientists to gain firsthand knowledge of solutions to real-world challenges in the development of nanoscale formulations.
Attendees will include scientists (B.S.-Ph.D.) from Boston-area biopharmaceutical companies. These scientists are eager to learn practical applications so that they are better equipped to perform their job. One-on-one sessions with speakers are available on a first come, first served basis. Complimentary breakfast and lunch provided, along with two facility tours during morning and afternoon breaks. Attendees will receive booklets of the relevant course information. The event will conclude with a networking cocktail reception. Limit of 50 seats available. Cost of $85 - no refunds.
Topics: The course will cover topics such as: The State of the Nanomedicine Industry; New Challenges and Frontiers in Polymer Characterization; Oral Formulations of Small Molecule Nanocrystals;Nanoparticle Formulations of siRNA; Nanotechnology Approaches to Tumor Targeting; andCharacterization of Disorder by Solid State Analytical Methods: Challenges upon Transition from Macroscopic to Nano Length Scales.
Speakers: Roy Haskell, Ph.D., Research Fellow, Discovery Pharmaceutics, Bristol-Myers Squibb; Eugene Zhorov, Ph.D.; Karen Thompson, Ph.D., Distinguished Research Investigator, Pharmaceutical Research, Merck; Muthiah Manoharan, Ph.D., Senior Vice President, Drug Discovery, Alnylam; Caroline McGregor, Ph.D., Director, Basic Pharmaceutical Sciences, Merck; Ales Medek, Ph.D., Scientific Fellow, Vertex Pharmaceuticals
To request an invitation: e-mail firstname.lastname@example.org.